| Literature DB >> 29843469 |
Chandan K Jha1, Rashid Mir2, Naina Khullar3, Shaheena Banu4, S M S Chahal5.
Abstract
PURPOSE: The low-density lipoprotein receptor is responsible for the binding and uptake of plasma LDL particles and plays a critical role in maintaining cellular cholesterol homeostasis. LDLR gene SNP rs688 has been reported to be associated with increased plasma total and LDL cholesterol in several populations and can lead to elevated plasma LDL levels, resulting in an increased risk for atherosclerosis and coronary artery disease. This study aimed to explore genetic LDLR variant rs688 for its potential roles in coronary artery disease.Entities:
Keywords: CAD—coronary artery disease; CI—confidence interval; LDLR rs688C/T; LDLR—low-density lipoprotein receptor; OR—odds ratio; SNP—single-nucleotide polymorphism; allele specific PCR
Year: 2018 PMID: 29843469 PMCID: PMC6023456 DOI: 10.3390/jcdd5020031
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425
Allele specific PCR primers for LDLR-rs688C/T gene polymorphism.
| Primer Sequence | Product Size | ||
|---|---|---|---|
| Forward F1 | C allele | 5′-CACTCCATCTCAAGCATCGATGTCAAC-3′ | 191 bp |
| Forward F2 | T allele | 5′-CACTCCATCTCAAGCATCGATGTCAAT-3′ | |
| Reverse | 5′-CAACCAGTTTTCTGCGTTCATCTTG-3′ | ||
| Amino acid change | N [Asn591] ⇒ N [Asn591] | ||
| Nucleotide change | C/T (FWD) | ||
Preparation of PCR cocktail for LDLR-rs688C > T polymorphism.
| Reagent | 1× |
|---|---|
| PCR master mix | 10 μL |
| Forward primer F1 | 0.35 μL |
| Forward primer F2 | 0.35 μL |
| Reverse primer R | 0.30 μL |
| Nuclease free water | 12 μL |
| Total volume | 23 μL |
| Finally add | 2 μL DNA |
| Total volume | 25 μL |
Figure 1Genotyping of the LDLR rs688 (C/T) polymorphism by an allele-specific PCR assay. A 191-bp DNA fragment indicated the presence of the allele, while amplification failure indicated the bsence of the allele in the sample. In a 2% w/v agarose gel, L indicates molecular size standard, C and T indicate the product from reaction C and reaction T, respectively, amplifiled from selected DNA sample of each possible genotypes (CC, CT and TT) and H2O (negative control).
Baseline characteristics of CAD patients and controls.
| Variables | CAD Cases | Healthy Controls |
|---|---|---|
| 200 | 200 | |
| Gender difference | ||
| Males | 180 (90%) | 176 (88%) |
| Females | 20 (10%) | 24 (12%) |
| Age difference | ||
| Age ≤ 50 | 90 (45%) | 88 (44%) |
| Age > 50 | 110 (55%) | 112 (56%) |
|
| % | |
| Cholesterol | ||
| ≤200 mg | 176 | (88%) |
| >200 mg | 24 | (12%) |
| RBS | ||
| RBS ≤ 140 mg | 129 | (64.5%) |
| RBS > 140 mg | 71 | (35.5%) |
| HDL | ||
| ≤40 mg | 166 | (83%) |
| >40 mg | 34 | (17%) |
| LDL | ||
| ≤100 mg | 150 | (75%) |
| >100 mg | 50 | (25%) |
| TGL | ||
| ≤150 mg | 105 | (52.5%) |
| >150 mg | 95 | (47.5%) |
| Yes | 23 | 11.5% |
| No | 177 | 88.5% |
| Hypertension | ||
| Yes | 53 | 26.5% |
| No | 147 | 73.5% |
| Type 2 Diabetes | ||
| Yes | 54 | 27% |
| No | 146 | 73% |
| Smoking | ||
| Yes | 121 | 60.5% |
| No | 79 | 39.5% |
| Alcohol | ||
| Yes | 71 | 35.5% |
| No | 129 | 64.5% |
| Pan Masala | ||
| Yes | 4 | 2% |
| No | 196 | 98% |
Allele and genotype frequency of LDLR gene polymorphism of study cohorts.
| Subjects | N= | C/C | C/T | T/T | DF | X2 | |
|---|---|---|---|---|---|---|---|
| Correlation with gender | |||||||
| Males | 180 | 25 | 117 | 38 | 0.03 | 2 | 0.98 |
| Females | 20 | 03 | 13 | 04 | |||
| Correlation with Age | |||||||
| Age ≤ 50 | 90 | 12 | 64 | 14 | 3.3 | 2 | 0.19 |
| Age > 50 | 110 | 16 | 66 | 28 | |||
| Correlation with RBS | |||||||
| RBS ≤ 140 mg | 129 | 17 | 86 | 26 | 0.45 | 2 | 0.79 |
| RBS > 140 mg | 71 | 11 | 44 | 16 | |||
| Correlation with Cholesterol | |||||||
| Cholesterol ≤ 200 mg | 176 | 25 | 112 | 39 | 1.4 | 2 | 0.49 |
| Cholesterol > 200 mg | 24 | 03 | 18 | 03 | |||
| Correlation with HDL | |||||||
| HDL ≤ 40 mg | 166 | 25 | 104 | 37 | 2.39 | 2 | 0.30 |
| HDL > 40 mg | 34 | 03 | 26 | 05 | |||
| Correlation with LDL | |||||||
| LDL ≤ 100 mg | 150 | 20 | 97 | 33 | 0.49 | 2 | 0.78 |
| LDL > 100 mg | 50 | 08 | 33 | 09 | |||
| Correlation with TGL | |||||||
| TGL ≤ 150 mg | 105 | 16 | 66 | 23 | 0.48 | 2 | 0.78 |
| TGL > 150 mg | 95 | 12 | 64 | 19 | |||
| Correlation with hypertension | |||||||
| Hypertension | 53 | 10 | 32 | 11 | 1.46 | 2 | 0.48 |
| No hypertension | 147 | 18 | 98 | 31 | |||
| Correlation with Diabetes | |||||||
| Diabetes | 54 | 07 | 34 | 13 | 0.44 | 2 | 0.80 |
| No Diabetes | 146 | 21 | 96 | 29 | |||
| Correlation with CHD | |||||||
| CHD | 23 | 07 | 11 | 05 | 6.2 | 2 | 0.04 |
| No CHD | 177 | 21 | 119 | 37 | |||
| Correlation with smoking | |||||||
| Smoking | 121 | 16 | 84 | 21 | 2.99 | 2 | 0.22 |
| No Smoking | 79 | 12 | 46 | 21 | |||
| Correlation with alcohol | |||||||
| Alcohol | 71 | 09 | 46 | 16 | 0.26 | 2 | 0.87 |
| No Alcohol | 129 | 19 | 84 | 26 | |||
Genotype frequency of LDLR rs688C > T polymorphism of study cohorts.
| Allele/Genotype | C/C | C/T | T/T | Chi-Square |
| |
|---|---|---|---|---|---|---|
| CAD patients | 28 (14%) | 130 (65%) | 42 (21%) | 11.53 | 2 | 0.0031 |
| Controls | 36 (18%) | 146 (73%) | 18 (9%) |
Association of LDLR rs688C > T gene variation with CAD.
| Genotypes | Healthy Controls | CAD Cases | OR (95% CI) | Risk Ratio (RR) | |||
|---|---|---|---|---|---|---|---|
| ( | % | ( | % | ||||
| Codominant model | |||||||
| LDLR-CC | 36 | 28 | Ref | Ref | |||
| LDLR-CT | 146 | 130 | 1.14 (0.66–1.97) | 1.06 (0.883–1.35) | 0.62 | ||
| LDLR-TT | 18 | 42 | 3.0 (1.43–6.2) | 1.87 (1.20–2.91) | 0.0037 | ||
| Dominant model | |||||||
| LDLR-CC | 36 | 28 | Ref | Ref | |||
| LDLR-(CT + TT) | 164 | 172 | 1.34 (0.78–2.30) | 1.15 (0.90–1.46) | 0.250 | ||
| Recessive model | |||||||
| LDLR-(CC + CT) | 182 | 312 | Ref | Ref | |||
| LDLR-TT | 18 | 42 | 1.36 (0.76–2.43) | 1.22 (0.82–1.83) | 0.310 | ||
| Allele | |||||||
| LDLR-C | 218 | 340 | Ref | Ref | |||
| LDLR-T | 182 | 214 | 0.74 (0.57–0.96) | 0.85 (0.73–0.98) | 0.032 | ||
Frequency of LDLR rs688C/T in different countries.
| Country | Subjects | N= | CC | % | CT | % | TT | % | |
|---|---|---|---|---|---|---|---|---|---|
| Taiwan | Cases | 447 | 295 | 66 | 143 | 32 | 9 | 2 | [ |
| controls | 430 | 292 | 68 | 121 | 28 | 17 | 4 | ||
| United States | Cases | 84 | 21 | 25 | 45 | 53.6 | 18 | 21.4 | [ |
| controls | 69 | 29 | 42 | 30 | 43.5 | 10 | 14.5 | ||
| Iran | Cases | 170 | 55 | 32.35 | 79 | 46.47 | 36 | 21.18 | [ |
| controls | 104 | 41 | 39.81 | 48 | 45.63 | 15 | 14.56 | ||
| Taiwan | Cases | 815 | 538 | 66 | 251 | 30.8 | 26 | 3.2 | [ |
| controls | 430 | 295 | 68.6 | 118 | 27.45 | 17 | 3.95 | ||
| Italy | Cases | 692 | 208 | 30.1 | 335 | 48.4 | 149 | 21.5 | [ |
| controls | 291 | 109 | 37.5 | 123 | 42.3 | 59 | 20.2 | ||
| India | Cases | 200 | 28 | 14 | 130 | 65 | 42 | 21 | |
| controls | 200 | 36 | 18 | 146 | 73 | 18 | 9 |